Genmab A/S (CPH:GMAB)
1,805.50
+87.00 (5.06%)
Jun 30, 2026, 4:15 PM CET
Genmab Market Cap
Genmab has a market cap or net worth of 105.5 billion as of June 30, 2026. Its market cap has increased by 15.39% in one year.
Market Cap
105.50B
Enterprise Value
130.31B
Revenue
25.29B
Ranking
n/a
PE Ratio
20.22
Stock Price
1,805.50
Market Cap Chart
Since October 18, 2000, Genmab's market cap has increased from 3.68B to 105.50B, an increase of 2,763.70%. That is a compound annual growth rate of 13.94%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 29, 2026 | 105.50B | -15.50% |
| Dec 30, 2025 | 124.86B | 31.70% |
| Dec 30, 2024 | 94.81B | -32.65% |
| Dec 29, 2023 | 140.77B | -26.77% |
| Dec 30, 2022 | 192.23B | 11.72% |
| Dec 30, 2021 | 172.06B | 6.80% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Novo Nordisk | 1.41T |
| Coloplast | 85.99B |
| Demant | 56.10B |
| ALK-Abelló | 55.61B |
| H. Lundbeck | 40.51B |
| Zealand Pharma | 20.00B |
| Ambu A/S | 16.08B |
| Bavarian Nordic | 13.69B |